Skip to main content
Home > Week in Review > Clinical Status

Chronological Index of : Clinical Status

 Current Issue
  • 19-28z CAR T cells: Phase II resumed

    Juno Therapeutics Inc. (NASDAQ:JUNO), Seattle, Wash. Product: 19-28z CAR T cells (JCAR015) Business: Cancer Molecular target: CD19 Description: Autologous T cells expressing the 19-28z chimeric antigen receptor (CAR) …

    Published on 7/18/2016
  • AIR DNase: Phase II started

    Protalix BioTherapeutics Inc. (NYSE-M:PLX; Tel Aviv:PLX), Carmiel, Israel Product: AIR DNase (PRX-110) Business: Pulmonary Molecular target: Deoxyribonuclease I (DNASE1) Description: Inhaled recombinant human …

    Published on 7/18/2016
  • ALN-HBV: Phase I/II started

    Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), Cambridge, Mass. Product: ALN-HBV Business: Infectious Molecular target: NA Description: RNAi therapeutic targeting the HBV genome and uses Enhanced Stabilization Chemistry (…

    Published on 7/18/2016
  • Ameluz aminolevulinic acid: Phase III started

    Biofrontera AG (Xetra:B8F), Leverkusen, Germany Product: Ameluz aminolevulinic acid (BF-200 ALA) Business: Dermatology Molecular target: Not available Description: Photodynamic therapy (PDT) comprising nanoemulsion BF-…

    Published on 7/18/2016
  • AZD4635: Phase I started

    Sosei Group Corp. (Tokyo:4565), Tokyo, Japan AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: AZD4635, HTL1071 Business: Cancer Molecular target: Adenosine A2A receptor (ADORA2A) Description: Small molecule …

    Published on 7/18/2016
  • BGB-3111: Phase I started

    BeiGene Ltd. (NASDAQ:BGNE), Beijing, China Product: BGB-3111 Business: Cancer Molecular target: Brutons tyrosine kinase (Btk) Description: Selective oral Brutons tyrosine kinase (Btk) inhibitor Indication: Treat B cell …

    Published on 7/18/2016
  • BGB-3111: Phase I started

    BeiGene Ltd. (NASDAQ:BGNE), Beijing, China Product: BGB-3111 Business: Cancer Molecular target: Brutons tyrosine kinase (Btk) Description: Selective oral Brutons tyrosine kinase (Btk) inhibitor Indication: Treat B cell …

    Published on 7/18/2016
  • BGB-A317: Phase I started

    BeiGene Ltd. (NASDAQ:BGNE), Beijing, China Product: BGB-A317 Business: Cancer Molecular target: Programmed cell death 1 (PD-1) (PDCD1) (CD279) Description: Humanized IgG4 mAb against PD-1 Indication: Treat B cell …

    Published on 7/18/2016
  • Cavosonstat: Completed Phase II enrollment

    Nivalis Therapeutics Inc. (NASDAQ:NVLS), Boulder, Colo. Product: Cavosonstat (N91115) Business: Pulmonary Molecular target: Alcohol dehydrogenase 5 (ADH5) (GSNOR) Description: Oral alcohol dehydrogenase 5 (ADH5; GSNOR) …

    Published on 7/18/2016
  • CK-2127107: Phase II started

    Cytokinetics Inc. (NASDAQ:CYTK), South San Francisco, Calif. Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Product: CK-2127107, CK-107 Business: Musculoskeletal Molecular target: Sarcomere Description: Fast skeletal …

    Published on 7/18/2016
  • Durvalumab: Phase I started

    AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: Durvalumab (MEDI4736) Business: Cancer Molecular target: Programmed cell death 1 ligand 1 (PD-L1) (B7-H1) (CD274) Description: Human IgG1 mAb targeting PD-L1 …

    Published on 7/18/2016
  • Faldaprevir: Phase IIa started

    Trek Therapeutics PBC, Cambridge, Mass. Boehringer Ingelheim GmbH, Ingelheim, Germany Product: Faldaprevir (BI 201335) Business: Infectious Molecular target: HCV NS3/4A protease complex Description: Oral HCV NS3/4A …

    Published on 7/18/2016
  • GSK3359609: Phase I started

    GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Product: GSK3359609 Business: Cancer Molecular target: Inducible T cell co-stimulator (ICOS) Description: Inducible T cell co-stimulator (ICOS) agonist antibody …

    Published on 7/18/2016
  • Imeglimin: Completed Phase IIb enrollment

    Poxel S.A. (Euronext:POXEL), Lyon, France Product: Imeglimin Business: Endocrine/Metabolic Molecular target: NA Description: Inhibitor of mitochondrial permeability transition pore (PTP) opening Indication: Treat Type …

    Published on 7/18/2016
  • Lidocaine vaginal gel: Completed Phase IIb enrollment

    Juniper Pharmaceuticals Inc. (NASDAQ:JNP), Boston, Mass. Product: Lidocaine vaginal gel (COL-1077) Business: Neurology Molecular target: Sodium channel Description: Lidocaine bioadhesive 10% vaginal gel Indication: …

    Published on 7/18/2016
  • ONCOS-102: Phase Ib/II started

    Targovax A/S, Oslo, Norway Product: ONCOS-102 (formerly CGTG-102) Business: Cancer Molecular target: NA Description: Modified tumor-targeted human serotype 5/3 adenovirus carrying the gene for GM-CSF Indication: Treat …

    Published on 7/18/2016
  • QGC101: Phase IIa started

    Quantum Genomics Corp. (Euronext:ALQGC), Paris, France Product: QGC101 Business: Cardiovascular Molecular target: Glutamyl aminopeptidase (ENPEP) Description: Glutamyl aminopeptidase (ENPEP) inhibitor Indication: Treat …

    Published on 7/18/2016
  • TD-6450: Phase IIa started

    Trek Therapeutics PBC, Cambridge, Mass. Theravance Biopharma Inc. (NASDAQ:TBPH), South San Francisco, Calif. Product: TD-6450 Business: Infectious Molecular target: HCV NS5A protein Description: Multivalent HCV NS5A …

    Published on 7/18/2016
  • Tenapanor: Phase IIb amended

    Ardelyx Inc. (NASDAQ:ARDX), Fremont, Calif. Product: Tenapanor (AZD1722, RDX5791) Business: Endocrine/Metabolic Molecular target: Solute carrier family 9 sodium hydrogen exchanger member 3 (SLC9A3) (NHE3) Description: …

    Published on 7/18/2016
  • ZYN002: Phase II started

    Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE), Radnor, Pa. Product: ZYN002 Business: Neurology Molecular target: NA Description: Synthetic cannabidiol (CBD) formulated as a transdermal gel Indication: Treat refractory …

    Published on 7/18/2016
  • 19-28z CAR T cells: Phase II halted

    Juno Therapeutics Inc. (NASDAQ:JUNO), Seattle, Wash. Product: 19-28z CAR T cells (JCAR015) Business: Cancer Molecular target: CD19 Description: Autologous T cells expressing the 19-28z chimeric antigen receptor (CAR) …

    Published on 7/11/2016
  • AADvac1: Phase II started

    Axon Neuroscience SE, Larnaca, Cyprus Product: AADvac1 Business: Neurology Molecular target: NA Description: Active vaccine containing synthetic peptide derived from microtubule-associated protein tau (tau; MAPT; FTDP-…

    Published on 7/11/2016
  • BC8-I-131: Phase III started

    Actinium Pharmaceuticals Inc. (NYSE-M:ATNM), New York, N.Y. Product: BC8-I-131, Iomab-B Business: Cancer Molecular target: CD45 Description: Anti-CD45 mAb (BC8) labeled with iodine-131 Indication: Improve outcomes of …

    Published on 7/11/2016
  • BNC210: Completed Phase II enrollment

    Bionomics Ltd. (ASX:BNO; OTCQX:BNOEF), Thebarton, Australia Product: BNC210 Business: Neurology Molecular target: Nicotinic acetylcholine receptor alpha 7 (CHRNA7) Description: Negative allosteric modulator of nicotinic…

    Published on 7/11/2016
  • CA-170: Phase I started

    Aurigene Discovery Technologies Ltd., Bangalore, India Curis Inc. (NASDAQ:CRIS), Lexington, Mass. Product: CA-170 (formerly AUPM-170) Business: Cancer Molecular target: Programmed cell death 1 ligand 1 (PD-L1) (B7-H1) (…

    Published on 7/11/2016

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993